Printer Friendly

COMPANY INFORMATION
MIGENIX Inc. 102-2389 Health Sciences Mall Vancouver, BC V6T 1Z3 Tel: (604) 221-9666 Toll-free: (800) 665-1968 Fax: (604) 221-9688 Contact Name Arthur J. Ayres Industry Biotechnology		Key Executives Paul A. Brennan, CEO Researches, develops and commercializes product candidates in the areas of infectious and degenerative diseases. Operations consist principally of research and development activities to advance the company's drug candidates through the product development and regulatory processes to obtain marketing approval.
FP ADVISOR COVERAGE MIGENIX Inc. • FP Corporate Analyzer • FP Directory of Directors • FP Corporate Surveys • FP Investor Reports • FP Predecessor & Defunct • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 309,546 Angiotech Pharmaceuticals, Inc. 302,251 QLT Inc. 132,457 Oncothyreon Inc. 42,678 AEterna Zentaris Inc. 41,056 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX/MGI $0.06 $0.20 $0.03 n.a. n.a. n.a. 0.34 Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 93,461 1.50 $0.04 Oct. 31/09 -45.45% -52.46% -39.01% $8,502
ANNUAL FINANCIALS Periods ended: 12m Apr. 30/09 12m Apr. 30/08 12m Apr. 30/07 $000s $000s $000s Operating revenue 198 6 19 Net income (562) (12,765) (16,052) Total assets 3,381 8,466 19,581 $ $ $ Earnings per share* (0.01) (0.14) (0.19) % % % Return on equity (43.70) (196.69) (124.92)   * Common
TRAILING 12-MONTH VALUES Periods ended: Oct. 31/09 Oct. 31/08 $000s $000s Operating revenue 170 28 Net income 3,953 (12,634) $ $ Earnings per share 0.02 (0.14)

COMPANY NEWS

Results for 'MIGENIX Inc.' from past 30 days: No hits. (Links are to articles.)